High prevalence of myocardial monoclonal antimyosin antibody uptake in patients with chronic idiopathic dilated cardiomyopathy

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Monoclonal antimyosin antibody studies were undertaken to assess the presence of myocardial uptake in patients with chronic idiopathic dilated cardiomyopathy. Three groups were studied: 17 patients with chronic (greater than 12 months) idiopathic dilated cardiomyopathy, 12 patients with a large, poorly contracting left ventricle not due to dilated cardiomyopathy (control patients) and 8 normal individuals. The patients in the cardiomyopathy and control groups showed a similar degree of clinical and functional impairment. Imaging was undertaken 48 h after antimyosin injection. The heart/lung ratio of antimyosin uptake was used to assess the results. The mean ratio in the cardiomyopathy group was 1.83 +/- 0.36 (range 1.40 to 2.80), a value significantly higher than that obtained in the control patients without cardiomyopathy (mean 1.46 +/- 0.04, range 1.38 to 1.50) or normal subjects (mean 1.46 +/- 0.13, range 1.31 to 1.6) (p less than 0.01). No difference in the ratio was noted between the normal subjects and control patients. Abnormal antimyosin uptake was seen in 12 (70%) of the 17 patients with cardiomyopathy and in only 1 (8%) of the 12 control patients. Positive monoclonal antimyosin antibody studies are highly prevalent in chronic idiopathic dilated cardiomyopathy.

This article has been cited by other articles:

				B. L.J.H. Kietselaer, C. P.M. Reutelingsperger, H. H. Boersma, G. A.K. Heidendal, I. H. Liem, H. J.G.M. Crijns, J. Narula, and L. Hofstra Noninvasive Detection of Programmed Cell Loss with 99mTc-Labeled Annexin A5 in Heart Failure J. Nucl. Med., April 1, 2007; 48(4): 562 - 567. [Abstract] [Full Text] [PDF]

				E. Miche, A. Radzewitz, G. Notohamiprodjo, D. Baller, A. Kloppe, S. Eckert, and U. Gleichmann [123I]-phenylpentadecanoic acid uptake in patients with dilated cardiomyopathy Eur J Heart Fail, August 1, 2002; 4(4): 431 - 438. [Abstract] [Full Text] [PDF]

				L. Sarda, P. Colin, F. Boccara, D. Daou, R. Lebtahi, M. Faraggi, C. Nguyen, A. Cohen, M. S. Slama, P. G. Steg, et al. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms J. Am. Coll. Cardiol., March 1, 2001; 37(3): 786 - 792. [Abstract] [Full Text] [PDF]

				G. Pons-Llado, M. Ballester, X. Borras, F. Carreras, I. Carrio, J. Lopez-Contreras, A. Roca-Cusachs, J. Marrugat, and J. Narula Myocardial cell damage in human hypertension J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2198 - 2203. [Abstract] [Full Text] [PDF]

				R. Serra-Grima, M. Estorch, I. Carrio, M. Subirana, L. Berna, and T. Prat Marked ventricular repolarization abnormalities in highly trained athletes' electrocardiograms: clinical and prognostic implications J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1310 - 1316. [Abstract] [Full Text] [PDF]

				L Sarda, P Assayag, E Palazzo, D Vilain, L Guillevin, M Faraggi, O Meyer, and D Le Guludec 111Indium antimyosin antibody imaging of primary myocardial invovement in systemic diseases Ann Rheum Dis, February 1, 1999; 58(2): 90 - 95. [Abstract] [Full Text]

				V. Marti, M. Ballester, C. Udina, I. Carrio, E. Alvarez, D. Obrador, and G. Pons-Llado Evaluation of Myocardial Cell Damage by In-111-Monoclonal Antimyosin Antibodies in Patients Under Chronic Tricyclic Antidepressant Drug Treatment Circulation, March 15, 1995; 91(6): 1619 - 1623. [Abstract] [Full Text]

				J. Bergler-Klein, H. Sochor, G. Stanek, S. Globits, R. Ullrich, and D. Glogar Indium 111--Monoclonal Antimyosin Antibody and Magnetic Resonance Imaging in the Diagnosis of Acute Lyme Myopericarditis Arch Intern Med, December 13, 1993; 153(23): 2696 - 2700. [Abstract] [PDF]